The objective of this observational study is to collect and evaluate data on Health Related Quality of Life (HRQoL) of Spiriva delivered by HandiHaler, using disease specific SGRQ in the national samples of Central & Central European patients with varying severities of chronic obstructive pulmonary disease (COPD) in the real life setting over the 6 months.

Study Design:

an open-label, uncontrolled and single arm post-marketing surveillance study

Inclusion criteria:

• 40 years and older male and female ambulatory outpatients.
• Clinical diagnosis of Chronic Obstructive Lung Disease (COPD) (Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines: Forced expiratory Volume in one second (FEV1)/ Forced Vital Capacity (FVC) < 0.7 and FEV1 < 80% predicted).
• Stable patient, without exacerbation for at least one month to the study.

Exclusion criteria:

• Uncooperative patients as judged by the physician.
• Patients that have any condition which, according to the participating physician's opinion, might decrease the chance of obtaining satisfactory data to achieve the objectives of the observation study.
• Patients with any conditions excluded as per Country specific package insert.
• Patients currently enrolled in another clinical trial which requires a change in medication for their respiratory problems.

patients